Sinopharm Group Co (X2S) Financial Statements
Sinopharm Group Co Financial Overview
Sinopharm Group Co's market cap is currently $5.75B. The company's EPS TTM is $2.25; its P/E ratio is 6.11; and it has a dividend yield of 4.27%. Sinopharm Group Co is estimated to report earnings on March 19, 2027, and the estimated EPS forecast is $0.16. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 575.17B | $ 584.51B | $ 596.57B | $ 552.15B | $ 521.05B |
| Gross Profit | $ 41.67B | $ 44.26B | $ 48.51B | $ 47.43B | $ 44.05B |
| Operating Income | $ 16.04B | $ 16.19B | $ 20.21B | $ 20.60B | $ 19.71B |
| EBITDA | $ 21.52B | $ 22.56B | $ 26.90B | $ 26.25B | $ 24.68B |
| Net Income | $ 7.16B | $ 7.05B | $ 9.05B | $ 8.53B | $ 7.76B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 61.59B | $ 54.31B | $ 63.81B | $ 55.22B | $ 43.54B |
| Total Assets | $ 390.53B | $ 392.83B | $ 383.39B | $ 364.78B | $ 335.41B |
| Total Debt | $ 108.63B | $ 76.39B | $ 73.78B | $ 69.59B | $ 68.37B |
| Net Debt | $ 47.04B | $ 22.07B | $ 9.97B | $ 14.37B | $ 24.84B |
| Total Liabilities | $ 256.31B | $ 266.14B | $ 263.08B | $ 254.71B | $ 235.76B |
| Stockholders' Equity | $ 83.99B | $ 78.88B | $ 74.58B | $ 68.07B | $ 61.89B |
| Cash Flow | |||||
| Free Cash Flow | $ 12.52B | $ 9.58B | $ 14.84B | $ 18.55B | $ 7.05B |
| Operating Cash Flow | $ 14.14B | $ 11.55B | $ 17.17B | $ 20.96B | $ 9.31B |
| Investing Cash Flow | $ -963.89M | $ -3.75B | $ -944.53M | $ -3.59B | $ -1.27B |
| Financing Cash Flow | $ -18.69B | $ -17.29B | $ -7.64B | $ -5.69B | $ -14.69B |
Currency in CNY